All times are listed in CEST (Central European Summer Time)

José Baselga: Cancer’s fiercest opponent (ID 49)

Welcome address from ESMO (ID 474)

Lecture Time
10:00 - 10:04
Room
Berlin Hall
Date
Tue, 03.05.2022
Time
10:00 - 11:20
José Baselga: Cancer’s fiercest opponent (ID 49)

Introduction of the documentary (ID 475)

Lecture Time
10:04 - 10:08
Room
Berlin Hall
Date
Tue, 03.05.2022
Time
10:00 - 11:20
José Baselga: Cancer’s fiercest opponent (ID 49)

Documentary (ID 476)

Lecture Time
10:08 - 11:05
Room
Berlin Hall
Date
Tue, 03.05.2022
Time
10:00 - 11:20
PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Tumor Board 1: Investigating Novel Therapeutic Approaches (ID 269)

YO “HowTo” Session: How to move genomic profiling to clinical practice by multidisciplinary collaboration? (ID 3)

Clinical case presentation from the molecular tumor board (ID 18)

AstraZeneca - Controversies in Breast Cancer (ID 48)

Treatment beyond CDK4/6i - what comes next? (ID 471)

Lecture Time
12:00 - 12:15
Room
Cologne Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
AstraZeneca - Controversies in Breast Cancer (ID 48)

Q&A / discussion (ID 478)

Lecture Time
12:15 - 12:30
Room
Cologne Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Tumor Board 2: Evolving Management Paradigms for High-Risk Early-Stage HR+/HER2- Breast Cancer (ID 270)

YO “HowTo” Session: How to move genomic profiling to clinical practice by multidisciplinary collaboration? (ID 3)

Panel discussion on the implementation of genomic profiling in clinical practice by multidisciplinary collaboration (ID 19)

PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Post-session Questions (ID 271)

YO “HowTo” Session: How to move genomic profiling to clinical practice by multidisciplinary collaboration? (ID 3)

Closing remarks (ID 20)